A Drug Utilization Study to Evaluate Indicators of Adherence to the Risk Minimization Measures for Ritlecitinib Using Electronic Healthcare Data in Denmark, France, and Sweden

First published 21/05/2025

Last updated 21/10/2026

EU PAS number:

EUPAS1000000523

Study

Planned

Download as PDF

Documents

Study protocol

Initial protocol

B7981102 Ritlecitinib DUS Protocol V1.0 01Mar2024.pdf

English (625.12 KB - PDF) View document

Updated protocol

B7981102_PROTOCOL AMENDMENT 1_01SEP2026.pdf

First published: 29/09/2026

English (499.83 KB - PDF) View document

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

A Drug Utilization Study to Evaluate Indicators of Adherence to the Risk Minimization Measures for Ritlecitinib Using Electronic Healthcare Data in Denmark, France, and Sweden

Secondary tabs

Share this page